

Table S1. Demographics, symptoms, and endoscopic and histologic findings of control subjects and EoE patients before treatment.

	Age (y)	Sex	BMI	Symptoms	Endoscopic findings	Histological findings			
						Eosinophils/HPF	Permeability	Mast cells/HPF	IgG4 deposits
EoE patients									
1	41	Male	31.6	Odynophagia	Furrows, white exudates	38	High	10	+
2	64	Female	21.5	Dysphasia	Furrows, white exudates	35	High	10	+
3	45	Male	24.6	Odynophagia	Furrows	33	High	10	+
4	32	Female	19.1	Heartburn	Furrows, white exudates	22	High	10	+
5	51	Female	22.4	Odynophagia	Furrows	29	High	8	+
6	59	Male	27.1	Heartburn	Furrows, white exudates	23	High	4	+
7	54	Male	27.4	Dysphasia	Rings, furrows, white exudates	17	High	20	+
8	35	Male	20.8	Heartburn	Furrows, white exudates	69	High	12	+
9	20	Male	17.4	Heartburn	Rings, furrows, white exudates	48	High	17	+
10	41	Male	21.6	Nausea	Furrows, white exudates	20	High	8	+
11	35	Female	19.1	Dysphasia	Furrows	20	High	7	+
Controls									
12	65	Female	22.5	No	Normal	0	Normal	0	-
13	49	Female	17.7	No	Normal	0	Normal	0	-
14	69	Female	19.5	No	Normal	0	Normal	0	-
15	41	Male	19.8	No	Normal	0	Normal	0	-
16	45	Female	33.6	No	Normal	0	Normal	0	-
17	63	Female	28.9	No	Normal	0	Normal	0	-
18	61	Male	22.8	Heartburn	Normal	0	Normal	0	-
19	57	Male	25.9	No	Normal	0	Normal	0	-
20	57	Male	21.5	No	Normal	0	Normal	0	-
21	52	Male	28.4	No	Normal	0	Normal	0	-
22	27	Female	22.9	No	Normal	0	Normal	0	-

Abbreviation: BMI, body mass index; EoE, eosinophilic esophagitis, HPF, high-power field.

Table S2. Treatment, symptoms, endoscopic and histologic findings of EoE patients after treatment.

Table S2. Treatment, symptoms, endoscopic and histologic findings of 202 patients after treatment.							
Medication (months)		Symptoms	Endoscopic findings	Histologic findings			
				Eosinophils/HPF	Permeability	Mast cells/HPF	IgG4 deposits
First follow-up							
1	Vonoprazan 20 mg + topical steroid (5)	No symptoms	Shallow furrows	5	High	1	-
2	Vonoprazan 20 mg (3)	No symptoms	Shallow furrows	3	high	3	+
3	Vonoprazan 10 mg (9)	No symptoms	Furrows, white exudates	8	High	7	+
4	Vonoprazan 20 mg + topical steroid (7)	No symptoms	Shallow furrows	8	High	7	+
5	Vonoprazan 20 mg (9)	Odynophagia	Furrows	5	High	8	+
6	Vonoprazan 20 mg + topical steroid (4)	Heartburn	Shallow furrows	3	Decreased	2	-
7	Vonoprazan 20 mg (3)	Dysphasia	Furrows	2	Decreased	2	-
8	Vonoprazan 20 mg (28)	Heartburn	Furrows	15	High	13	+
9	Vonoprazan 10 mg (3)	No symptoms	Rings	72	High	8	+
10	Vonoprazan 20 mg + topical steroid (11)	Nausea	furrows, white exudates	20	High	5	+
11	Esomeprazole 20mg (2)	Dysphasia	Furrows	22	High	9	+
Second follow-up							
1	Vonoprazan 20 mg (11)	No symptoms	Normal	0	Decreased	1	-
2	Vonoprazan 10 mg (6)	No symptoms	Normal	0	Decreased	0	-
3	Vonoprazan 10 mg (14)	No symptoms	Normal	0	Decreased	0	-

Abbreviation: HPF, high-power field